Medical network - on May 18, according to UK media in HuaYao companies in product pricing under pressure, China increased the reimbursement drugs and drugs to speed up the approval or help them reverse slowing sales growth. 

 

According to England "financial times" web site reported on May 17, in the Chinese market is under pricing pressure on the world each big pharmaceutical companies hope that China's expanding access to medicines and speed up the approval process will help them to improve sales. 

 

China is already the world's second-largest pharmaceutical market, with sales of $116.7 billion in 2016, according to QuintilesIMS. But the spread of public health insurance has given provincial governments more power over drug pricing. 

 

The report said several companies reported slower sales growth in China, such as the 3% drop in Chinese sales in the first quarter of this year. Astrazeneca said sales in China rose 7 per cent to $782 million in the first quarter of this year, compared with 10 per cent in 2016 and 15 per cent in 2015. Sales in China rose 9 per cent in 2016, about half the pace of the previous year, Mr Sanofi said. 

 

Glaxosmithkline argues that in the first quarter of this year the "mature" products sales in China fell by 5%, in part because its hepatitis drug lamivudine in China is facing the pressure of competition. Its sales in China fell 12 per cent last year, according to the company, citing "healthcare reform including lower prices". 

 

The report says that multinational drug companies are having difficulty in the Chinese market, with the core reason that the model set up in the early 2000s has collapsed. In that mode, China allows foreign drug companies sales at higher price has brand drug patent protection, the price of this kind of medicine often 3 to 5 times the ordinary drugs. 

 

But, after 2011, along with public health insurance coverage, the market began to atrophy (into public health care medicines can reimburse 80%). The public health system contains tendering processes, where drug companies and provincial governments negotiate the price of drugs. Since then, prices have fallen as each province has negotiated the lowest prices agreed by other provinces. 

 

According to the report, China more than 80% of drug sales from public hospitals, over the past year Beijing has issued a new policy, banned public hospitals will they distribution of drugs price too high. 

 

Underfunded hospitals are finding ways to make up for less revenue by purchasing drugs cheaper than those in the provinces. That has led to the policy being an incentive to try to push down the price of drugs in the negotiations, says liu guoan, an expert on health economics at Peking University. 

 

Health care reform, there is a bright spot for drug firms: the government share the medical expenses reduce the burden of the patients, let more people to use drugs included in the scope of coverage. 

 

In February 2017, China decided to add 130 new drugs to the country on the basis of about 1,200 of the original western medicine. Multinational companies have praised the change, which will increase the use of their medicines in China. 

 

Into drug directory, however, with the pricing pressures, glaxosmithkline will its hepatitis drug viread in China last year prices fell by two-thirds, astrazeneca is the price of the anticancer drug Yi Rui sand halved. 

 

Last year, most multinational companies' sales in China rose more than the overall drug market in China, which was just 1 percent, the report said. This is partly because, with an ageing society and become more affluent, an outbreak of a new wave of chronic diseases in China, multinational company's products more adapt to this change. Sanofi said its oncology division was a performance star in China last year. 

 

The drug companies are also pinning their hopes on a draft regulation that will significantly accelerate drug approval processes. In China, drug approval processes may be five years longer than those in Europe and the United States. The proposed new rules would require the elimination of clinical trials of drugs outside the country to begin the process of approval in China. 

 

Sanofi emerging markets, says Mr Levy "- charmey director of the department of the proposed rules would mean that drugs in China and in developed economies" almost "at the same time. "As the middle class gets richer... they want to make sure they can use the most innovative drugs." 

 

However, drug companies will also face pricing pressures. China's state council has said, through the examination and approval of new drugs a premise is a promise to sell in China "the price is not higher than the country of origin or peripheral than the market price in China". 

 

China's health and family planning commission said it would negotiate a price reduction for 45 mainly patented drugs this year.